We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Randox Laboratories

Provides global diagnostic solutions for hospital laboratories, forensic laboratories, research laboratories, pharmac... read more Featured Products: More products

Download Mobile App




Rapid Bacterial Infection Test Differentiates Between MRSA and MSSA in 53 Minutes

By LabMedica International staff writers
Posted on 18 Jul 2023
Print article
Image: The Vivalytic MRSA/MSSA Rapid Test provides a quick diagnosis of methicillin resistance at the point of care (Photo courtesy of Randox)
Image: The Vivalytic MRSA/MSSA Rapid Test provides a quick diagnosis of methicillin resistance at the point of care (Photo courtesy of Randox)

Methicillin-resistant Staphylococcus aureus (MRSA) is a critical pathogen responsible for numerous hospital-acquired infections, leading to complications and increased mortality rates. The World Health Organization has estimated that patients infected with MRSA experience a mortality rate approximately 50% higher than those affected by non-resistant strains of Staphylococcus aureus. Therefore, swiftly and accurately determining whether the bacterial strain is methicillin-sensitive (MSSA) or resistant is crucial, particularly in emergency situations. Conducting MRSA/SA screening plays a significant role in mitigating health risks by curtailing contamination, breaking the chain of infection, and combating superbugs and antimicrobial resistance. Now, a rapid test provides differentiation between MRSA and MSSA in 53 minutes at the point of care.

The Vivalytic MRSA/MSSA Rapid Test from Randox Laboratories (Crumlin, UK) is a qualitative RT-PCR diagnostic test capable of identifying and distinguishing MRSA, MSSA, and methicillin-resistant coagulase-negative Staphylococci (MRCoNS). Using a single cartridge, the Vivalytic MRSA/MSSA test facilitates a speedy diagnosis of MRSA infections, allowing for the immediate application of suitable antibiotic treatment and prevention of complications. In contrast to the 1-3 days required for traditional culture sampling, the Vivalytic test provides reliable results in less than an hour right at the point of care, making it highly applicable for use in emergency departments.

The Vivalytic analyzer has been designed to be user-friendly, delivering speedy analyses and ease of handling. The patient-to-result process comprises a simple four-step procedure. The test commences when the user scans or inputs sample information and then scans the cartridge code into the integrated Vivalytic software. The sample is then added into the cartridge slot, after which the lid is closed, and the cartridge is inserted into the Vivalytic. The touchscreen display provides a countdown to the completion of the test, and results are shown on the screen. Furthermore, multiple Vivalytic devices can be wirelessly linked, enabling simultaneous control of multiple tests, all reporting to a primary Vivalytic platform.

Related Links:
Randox Laboratories 

Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
New
Urine Drug Test
Instant-view Propoxyphene Urine Drug Test
New
DNA Extraction Kit
Ron’s Gel Extraction Mini Kit

Print article

Channels

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.